Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12345678910111213...136137»
  • ||||||||||  Journal:  Ultrasound-Guided Aspiration of a Paralabral Cyst: A Novel Technique for Management. (Pubmed Central) -  Oct 11, 2024   
    In summary, paralabral cysts present a complex clinical challenge that benefits from individualized treatment plans. In addition, this case highlights the importance of inter-professional communication and patient-centered care in exploring viable alternatives to surgery, such as ultrasound-guided aspiration, which provides significant symptom relief and functional improvement.
  • ||||||||||  Retrospective data, Journal:  Single simple question in axonal polyneuropathy. (Pubmed Central) -  Oct 11, 2024   
    The SSQ is a feasible, valid scale that may be utilized to assess and follow patients with length-dependent axonal PNPs. Given that the SSQ is not strongly associated with clinical and disability scales or electrophysiological findings, additional investigations are required for a comprehensive assessment of PNP.
  • ||||||||||  Journal:  Possible sex and racial disparities in myasthenia gravis care. (Pubmed Central) -  Oct 11, 2024   
    We found healthcare disparities in MG treatment with female and Black patients receiving less treatment than men and those of other races/ethnicities. Further research and detailed assessments accounting for individual patient factors are needed to confirm these apparent disparities.
  • ||||||||||  Retrospective data, Review, Journal:  Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma. (Pubmed Central) -  Oct 10, 2024   
    NF-Abs were only seen among patients with CNS disorders. At onset, the absence of a primary skin tumor but presence of lymph node metastasis is frequently observed, and this particular clinical presentation is linked to reduced mortality, highlighting distinctive clinical and immunologic features of MCC-related PNS.
  • ||||||||||  Journal:  Lipoprotein Receptor-Related Protein 4 Antibody Positivity in the Youngest Patient in the Caucasus Region: A Case Report. (Pubmed Central) -  Oct 10, 2024   
    This case exemplifies the very rare association of juvenile myasthenia gravis with low-density lipoprotein receptor-related protein 4 positivity, reported in only a few cases so far. The specificity of the antibody and the efficiency of medical treatment emphasize the importance of clinical suspicion and appropriate serological testing in juvenile myasthenia gravis in the absence of acetylcholine receptor and muscle-specific kinase antibodies.
  • ||||||||||  Review, Journal:  Prevalence, incidence, and mortality of Myasthenia Gravis and myasthenic syndromes: a systematic review. (Pubmed Central) -  Oct 9, 2024   
    The prevalence and incidence of MG have significantly increased over the last years worldwide, probably due to the improvement of epidemiological methodologies and current advances in diagnosis. However, we observed a significant variation in frequencies of MG between and within countries because of methodological biases and complex heterogeneity of the disease characterized by several phenotypes and different clinical responses.
  • ||||||||||  Journal:  MuSK-Myasthenia Gravis and Cancer. (Pubmed Central) -  Oct 8, 2024   
    However, we observed a significant variation in frequencies of MG between and within countries because of methodological biases and complex heterogeneity of the disease characterized by several phenotypes and different clinical responses. No abstract available
  • ||||||||||  Review, Journal, IO biomarker:  The spectrum of rippling muscle disease. (Pubmed Central) -  Oct 7, 2024   
    Different pathogenic mechanisms have been postulated to explain the disease mechanisms. In this article, we review the spectrum of hRMD and iRMD, including clinical phenotypes, electrophysiological characteristics, myopathological findings, and pathogenesis.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Review, Journal, Checkpoint inhibition:  Association Between the Immune Checkpoint Inhibitor Durvalumab and Myasthenia Gravis: A Comprehensive Review. (Pubmed Central) -  Oct 4, 2024   
    The clinical consequences of MG need meticulous monitoring, prompt identification, and suitable management to efficiently control the condition. Medical practitioners must carefully weigh the positive effects of ICIs against the possible hazards, emphasizing the necessity for more extensive investigation to improve patient results and establish uniform treatment protocols.
  • ||||||||||  Journal:  Reply to "MuSK-Myasthenia Gravis and Cancer". (Pubmed Central) -  Oct 4, 2024   
    Medical practitioners must carefully weigh the positive effects of ICIs against the possible hazards, emphasizing the necessity for more extensive investigation to improve patient results and establish uniform treatment protocols. No abstract available
  • ||||||||||  Journal:  Acute Respiratory Failure Due to Inaugural Myasthenia Crisis. (Pubmed Central) -  Sep 30, 2024   
    The diagnosis of MC is clinical and relies on the presence of typical symptoms that can be absent, emphasizing the importance of attracting the attention of emergency physicians to this rare cause of respiratory failure. We present the case of a 66-year-old woman presenting to the emergency department with a history of recent muscle fatigue and dehydration who developed acute respiratory failure requiring mechanical ventilation.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Exhausted signature and regulatory network of NK cells in myasthenia gravis. (Pubmed Central) -  Sep 30, 2024   
    SOCS2 siRNA and IL-2 supplement attenuated the IL-6/IL-21-mediated alteration of NK-cell phenotypes and function. Inhibition of IL-6/IL-21/SOCS2/STAT5 pathway and recovery of NK-cell ability to inhibit autoimmunity may be a new direction in the treatment of MG.
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    AN UNUSUAL REACTION TO HIZENTRA (SUBCUTANEOUS IMMUNE GLOBULIN (HUMAN) 20% LIQUID) (Monitor 1; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1054;    
    Hizentra is a 20% solution that contains L-proline and polysorbate 80 whereas Privigen is a 10% solution with L-proline, and both have very low IgA content, <50 mcg/mL and <25 mcg/mL respectively. Urticarial Reaction to Subcutaneous Immune Globulin These recurring, pruritic, erythematous urticarial lesions were present on the arms and torso within hours of subcutaneous immune globulin infusion.
  • ||||||||||  Journal:  Epilepsy and Myasthenia Gravis: A Case Series. (Pubmed Central) -  Sep 29, 2024   
    In adult patients, epilepsy onset precedes myasthenia onset in most cases. In some cases, epilepsy has an autoimmune etiology and coexists with other autoimmune conditions.
  • ||||||||||  Remicade (infliximab) / J&J
    Journal:  Pearls & Oy-sters: Vocal Cord Palsy as the Presenting Manifestation of Neurosarcoidosis. (Pubmed Central) -  Sep 27, 2024   
    The patient was treated with pulse steroids and outpatient initiation of infliximab...This case illustrates cranial nerve X and XII palsy as the presentation of neurosarcoidosis. In addition, it demonstrates the value of CSF sIL-2R as a biomarker for neurosarcoidosis and highlights the growing popularity of using steroid-sparing agents for treatment to achieve better outcomes with fewer side effects.
  • ||||||||||  Review, Journal:  Non-Coding RNAs in Myasthenia Gravis: From Immune Regulation to Personalized Medicine. (Pubmed Central) -  Sep 27, 2024   
    The long ncRNA (lncRNA) contribution to MG, although not fully characterized yet, is also discussed. By summarizing the most recent and fast-growing findings on ncRNAs in MG, we highlight the therapeutic potential of these molecules for achieving immune regulation and their value as biomarkers for the development of personalized medicine approaches to improve disease care.
  • ||||||||||  Journal:  AI-Powered Telemedicine for Automatic Scoring of Neuromuscular Examinations. (Pubmed Central) -  Sep 27, 2024   
    This AI-powered solution offers a quantitative assessment of neurological deficits, improving upon subjective evaluations prone to examiner variability. It has the potential to enhance efficiency, patient participation in MG clinical trials, and broader applicability to various neurological diseases.